Journal Mobile Options
Table of Contents
Vol. 26, No. 3, 2006
Issue release date: July 2006
Am J Nephrol 2006;26:258–267
(DOI:10.1159/000093814)

Urinary Proteome of Steroid-Sensitive and Steroid-Resistant Idiopathic Nephrotic Syndrome of Childhood

Woroniecki R.P. · Orlova T.N. · Mendelev N. · Shatat I.F. · Hailpern S.M. · Kaskel F.J. · Goligorsky M.S. · O’Riordan E.
aSection of Pediatric Nephrology, Department of Pediatrics, and bDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, N.Y.; cRenal Institute, New York Medical College, Valhalla, N.Y., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The response to steroid therapy is used to characterize the idiopathic nephrotic syndrome (INS) of childhood as either steroid-sensitive (SSNS) or steroid-resistant (SRNS), a classification with a better prognostic capability than renal biopsy. The majority (∼80%) of INS is due to minimal change disease but the percentage of focal and segmental glomerulosclerosis is increasing. We applied a new technological platform to examine the urine proteome to determine if different urinary protein excretion profiles could differentiate patients with SSNS from those with SRNS. Twenty-five patients with INS and 17 control patients were studied. Mid-stream urines were analyzed using surface enhanced laser desorption and ionization mass spectrometry(SELDI-MS). Data were analyzed using multiple bioinformatic techniques. Patient classification was performed using Biomarker Pattern SoftwareTM and a generalized form of Adaboost and predictive models were generated using a supervised algorithm with cross-validation. Urinary proteomic data distinguished INS patients from control patients, irrespective of steroid response, with a sensitivity of 92.3%, specificity of 93.7%, positive predictive value of 96% and a negative predictive value of 88.2%. Classification of patients as SSNS or SRNS was 100%. A protein of mass 4,144 daltons was identified as the single most important classifier in distinguishing SSNS from SRNS. SELDI-MS combined with bioinformatics can identify different proteomic patterns in INS. Characterization of the proteins of interest identified by this proteomic approach with prospective clinical validation may yield a valuable clinical tool for the non-invasive prediction of treatment response and prognosis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Habib R, Kleinknecht C: The primary nephrotic syndrome of childhood. Classification and clinicopathologic study of 406 cases. Pathol Annu 1971;6:417–474.
  2. Arneil GC: The nephrotic syndrome. Pediatr Clin North Am 1971;18:547–559.
  3. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978;13:159–165.
  4. Hodson E, Knight J, Willis N, Craig J: Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev:CD001533, 2005.
  5. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J: Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000;105:1242–1249.
  6. Warady BA, Hebert D, Sullivan EK, Alexander SR, Tejani A: Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. The 1995 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997;11:49–64.
  7. Chesney R: The changing face of childhood nephrotic syndrome. Kidney Int 2004;66:1294–1302.
  8. Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP: Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003;237:660–665.
  9. O’Riordan E, Orlova TN, Mei JJ, Butt K, Chander PM, Rahman S, Mya M, Hu R, Momin J, Eng EW, Hampel DJ, Hartman B, Kretzler M, Delaney V, Goligorsky MS: Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004;15:3240–3248.
  10. Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, Golovko I, Rupprecht HD, Haubitz M, Hecker H, Mischak H, Fliser D: Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004;65:2426–2434.
  11. Tencer J, Thysell H, Andersson K, Grubb A: Stability of albumin, protein HC, immunoglobulin G, κ- and λ-chain immunoreactivity, orosomucoid and α1-antitrypsin in urine stored at various conditions. Scand J Clin Lab Invest 1994;54:199–206.
  12. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P: Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65:323–332.
  13. Coombes KR, Fritsche HA Jr, Clarke C, Chen JN, Baggerly KA, Morris JS, Xiao LC, Hung MC, Kuerer HM: Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003;49:1615–1623.
  14. Breiman LFJ, Olshen R, Stone C: Classification and Regression Trees. Belmont/CA, Wadsworth, 1984.
  15. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr: Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from non-cancer patients. Clin Chem 2002;48:1835–1843.
  16. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T: Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, γ-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004;95:955–961.
  17. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, Nicolle L, Karpinski M, Jeffery J, Nickerson P: Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004;15:219–227.
  18. Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Knueppel S, Haller H, Fliser D: Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) 2004;107:485–495.
  19. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE: Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003;63:6971–6983.
  20. Chevalier RL: Biomarkers of congenital obstructive nephropathy: past, present and future. J Urol 2004;172:852–857.
  21. Hampel DJ, Sansome C, Sha M, Brodsky S, Lawson WE, Goligorsky MS: Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. J Am Soc Nephrol 2001;12:1026–1035.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50